Cyclosporine-induced immune suppression alters establishment of HTLV-1 infection in a rabbit model

Blood

Volumn 115, Issue 4, 2010, Pages 815-823

  Haynes II, Rashade A H ^a   Ware, Evan ^a   Premanandan, Christopher ^a   Zimmerman, Bevin ^a   Yu, Lianbo ^a   Phipps, Andrew J ^a   Lairmore, Michael D ^a,b  

^a OHIO STATE UNIVERSITY   (United States)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; PROTEIN P19; SODIUM CHLORIDE; GAG PROTEIN; GP46 PROTEIN, HUMAN T CELL LEUKEMIA VIRUS TYPE I; GP46 PROTEIN, HUMAN T-CELL LEUKEMIA VIRUS TYPE I; IMMUNOSUPPRESSIVE AGENT; ONCOPROTEIN; P19 PROTEIN, HUMAN T LYMPHOTROPIC VIRUS 1; P19 PROTEIN, HUMAN T-LYMPHOTROPIC VIRUS 1; VIRUS ENVELOPE PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG BLOOD LEVEL; EX VIVO STUDY; FEMALE; GENE EXPRESSION; HUMAN T CELL LEUKEMIA VIRUS 1; HUMAN T CELL LEUKEMIA VIRUS INFECTION; IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; INFECTION CONTROL; LONG TERM CARE; LYMPHOCYTE; NEW ZEALAND WHITE RABBIT; NONHUMAN; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RABBIT; SEROLOGY; TREATMENT DURATION; VIRUS LOAD; VIRUS REPLICATION; ANIMAL; BLOOD; CD4 CD8 RATIO; CYTOLOGY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; GENETICS; GROWTH, DEVELOPMENT AND AGING; HELPER CELL; HUMAN; IMMUNOCOMPROMISED PATIENT; IMMUNOLOGY; LEUKEMIA CELL LINE; LYMPHOCYTOSIS; METABOLISM; T CELL LYMPHOMA; TRANSPLANTATION; VIROLOGY;

ANIMALS; CD4-CD8 RATIO; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GAG GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; GENE PRODUCTS, ENV; HTLV-I INFECTIONS; HUMAN T-LYMPHOTROPIC VIRUS 1; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; JURKAT CELLS; LYMPHOCYTOSIS; LYMPHOMA, T-CELL; RABBITS; RETROVIRIDAE PROTEINS, ONCOGENIC; T-LYMPHOCYTES, HELPER-INDUCER; VIRAL LOAD;

EID: 77949329047     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-07-230912     Document Type: Article

References (50)

1. Mahieux R, Gessain A. HTLV-1 and associated adult T-cell leukemia/lymphoma. Rev Clin Exp Hematol. 2003;7:336-361. (Pubitemid 38248510)
2. Franchini G, Fukumoto R, Fullen JR. T-cell control by human T-cell leukemia/lymphoma virus type 1. Int J Hematol. 2003;78:280-296. (Pubitemid 37532383)
3. Peloponese JM Jr, Kinjo T, Jeang KT. Human Tcell leukemia virus type 1 Tax and cellular transformation. Int J Hematol. 2007;86:101-106. (Pubitemid 47425185)
4. Asquith B, Bangham CR. How does HTLV-I persist despite a strong cell-mediated immune response? Trends Immunol. 2008;29:4-11.
5. + cells in HTLV-1 infection: inverse correlation with HTLV-1-specific CTL response. Blood. 2008;111:5047-5053.
6. Imirizaldu JJ, Esteban JC, Axpe IR, et al. Posttransplantation HTLV-1 myelopathy in three recipients from a single donor. J Neurol Neurosurg Psychiatry. 2003;74:1080-1084. (Pubitemid 36936384)
7. Okamura J, Uike N, Utsunomiya A, et al. Allogeneic stem cell transplantation for adult T-cell leukemia/lymphoma. Int J Hematol. 2007;86:118-125. (Pubitemid 47425188)
8. Takizawa J, Aoki S, Kurasaki T, et al. Successful treatment of adult T-cell leukemia with unrelated cord blood transplantation. Am J Hematol. 2007;82:1113-1115. (Pubitemid 350209858)
9. Shiratori S, Yasumoto A, Tanaka J, et al. A retrospective analysis of allogeneic hematopoietic stem cell transplantation for adult T cell leukemia/lymphoma (ATL): clinical impact of graft-versusleukemia/lymphoma effect. Biol Blood Marrow Transplant. 2008;14:817-823.
10. Tsukasaki K, Maeda T, Arimura K, et al. Poor outcome of autologous stem cell transplantation for adult T cell leukemia/lymphoma: a case report and review of the literature. Bone Marrow Transplant. 1999;23:87-89. (Pubitemid 29050184)
11. Tajima K, Amakawa R, Uehira K, et al. Adult T-cell leukemia successfully treated with allogeneic bone marrow transplantation. Int J Hematol. 2000;71:290-293.
12. Gout O, Baulac M, Gessain A, et al. Medical inteligence: rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med. 1990;332:383-388.
13. Brezin AP, Gout O, Gessain A, et al. Uveitis associated with post-transfusional human T-lymphotropic virus type 1. Lancet. 1995;345:1246-1247.
14. Kotani S, Yoshimoto S, Yamato K, et al. Serial transmission of human T-cell leukemia virus type 1 by blood transfusion in rabbits and its prevention by use of X-irradiated stored blood. Int J Cancer. 1986;37:843-847.
15. Uemura Y, Kotani S, Yoshimoto S, et al. Oral transmission of human T-cell leukemia virus type-1 in the rabbit. Jpn J Cancer Res. 1986;77:970-973.
16. Hirose S, Kotani S, Uemura Y, et al. Milk-borne transmission of human T-cell leukemia virus type I in rabbits. Virology. 1988;162:487-489.
17. Miyoshi I. An animal model of adult T-cell leukemia research. Jpn J Med. 1989;28:410-412.
18. Cockerell GL, Weiser MG, Rovnak J, et al. Infectious transmission of human T-cell lymphotropic virus type II in rabbits. Blood. 1991;78:1532-1537.
19. + lymphocyte transformation and infection in a rabbit model with a molecular clone of human T-cell lymphotropic virus type 1. J Virol. 1996;70:7241-7246.
20. Hiraragi H, Kim SJ, Phipps AJ, et al. Human T-lymphotropic virus type 1 mitochondrionlocalizing protein p13II is required for viral infectivity in vivo. J Virol. 2006;80:3469-3476.
21. Lairmore MD, Digeorge AM, Conrad SF, et al. Human T-lymphotropic virus type 1 peptides in chimeric and multivalent constructs with promiscuous T-cell epitopes enhance immunogenicity and overcome genetic restriction. J Virol. 1995;69:6077-6089.
22. Kuroda Y, Takashima H. Impairment of cell mediated immune responses in HTLV-I-associated myelopathy. J Neurol Sci. 1990;100:211-216.
23. Tsurumi H, Tani K, Tsuruta T, et al. Adult T-cell leukemia developing during immunosuppressive treatment in a renal transplant recipient. Am J Hematol. 1992;41:292-294. (Pubitemid 23000034)
24. Jenks PJ, Barrett WY, Raftery MJ, et al. Development of human T-cell lymphotropic virus type Iassociated adult T-cell leukemia/lymphoma during immunosuppressive treatment following renal transplantation. Clin Infect Dis. 1995;21:992-993.
25. Hanabuchi S, Ohashi T, Koya Y, et al. Development of human T-cell leukemia virus type 1-transformed tumors in rats following suppression of T-cell immunity by CD80 and CD86 blockade. J Virol. 2000;74:428-435. (Pubitemid 30002924)
26. Ohashi T, Hanabuchi S, Kato H, et al. Induction of adult T-cell leukemia-like lymphoproliferative disease and its inhibition by adoptive immunotherapy in T-cell-deficient nude rats inoculated with syngeneic human T-cell leukemia virus type 1-immortalized cells. J Virol. 1999;73:6031-6040. (Pubitemid 29274890)
27. Kannagi M, Ohashi T, Hanabuchi S, et al. Immunological aspects of rat models of HTLV type 1-infected T lymphoproliferative disease. AIDS Res Hum Retroviruses. 2000;16:1737-1740.
28. Hanabuchi S, Ohashi T, Koya Y, et al. Regression of human T-cell leukemia virus type I (HTLV-I)-associated lymphomas in a rat model: peptideinduced T-cell immunity. J Natl Cancer Inst. 2001;93:1775-1783. (Pubitemid 33150449)
29. Nomura M, Ohashi T, Nishikawa K, et al. Repression of tax expression is associated both with resistance of human T-cell leukemia virus type 1-infected T cells to killing by tax-specific cytotoxic T lymphocytes and with impaired tumorigenicity in a rat model. J Virol. 2004;78:3827-3836.
30. Feuer G, Stewart SA, Baird SM, et al. Potential role of natural killer cells in controlling tumorigenesis by human T-cell leukemia viruses. J Virol. 1995;69:1328-1333.
31. Stewart SA, Feuer G, Jewett A, et al. HTLV-I gene expression in adult T-cell leukemia cells elicits an NK cell response in vitro and correlates with cell rejection in SCID mice. Virology. 1996;226:167-175. (Pubitemid 27025795)
32. + T cells from autologous natural killer cell-mediated cytotoxicity despite the reduction of major histocompatibility complex class I molecules on infected cells. J Virol. 2007;81:9707-9717.
33. Bangham CR, Meekings K, Toulza F, et al. The immune control of HTLV-1 infection: selection forces and dynamics. Front Biosci. 2009;14:2889-2903.
34. Mortreux F, Gabet AS, Wattel E. Molecular and cellular aspects of HTLV-1 associated leukemogenesis in vivo. Leukemia. 2003;17:26-38. (Pubitemid 36175884)
35. Willems L, Burny A, Collete D, et al. Genetic determinants of bovine leukemia virus pathogenesis. AIDS Res Hum Retroviruses. 2000;16:1787-1795.
36. Kazanji M, Ureta-Vidal A, Ozden S, et al. Lymphoid organs as a major reservoir for human Tcell leukemia virus type 1 in experimentally infected squirrel monkeys (Saimiri sciureus): provirus expression, persistence, and humoral and cellular immune responses. J Virol. 2000;74:4860-4867. (Pubitemid 30237914)
37. Florins A, Gillet N, Asquith B, et al. Cell dynamics and immune response to BLV infection: a unifying model. Front Biosci. 2007;12:1520-1531.
38. Ozaki A, Arima N, Matsushita K, et al. Cyclosporin A inhibits HTLV-I tax expression and shows anti-tumor effects in combination with VP-16. J Med Virol. 2007;79:1906-1913. (Pubitemid 350006317)
39. Collins ND, Newbound GC, Albrecht B, et al. Selective ablation of human T-cell lymphotropic virus type 1 p12I reduces viral infectivity in vivo. Blood. 1998;91:4701-4707. (Pubitemid 28270320)
40. Yoshida S, Sekine Y, Saitoh Y, et al. Surgical technique of experimental lung transplantation in rabbits. Ann Thorac Cardiovasc Surg. 2005;11:7-11.
41. Carvalho JB, Petroianu A, Travolo E, et al. Effects of immunosuppression induced by thalidomide and cyclosporine in heterotopic heart transplantation in rabbits. Transplant Proc. 2007;39:1640-1641. (Pubitemid 46907902)
42. Tesfaye H, Prusa R, Jedlickova B, et al. Cyclosporine use in miscellaneous clinical settings other than organ transplantations: is there any evidence for target levels? Ann Transplant. 2008;13:34-40.
43. Mohapatra N, Vanikar AV, Patel RD, et al. Modifying cyclosporine associated renal allograft dysfunction. Saudi J Kidney Dis Transpl. 2009;20:770-774.
44. Kahan BD. Forty years of publication of transplantation proceedings: the second decade: the cyclosporine revolution. Transplant Proc. 2009;41:1423-1437.
45. Ekberg H, Bernasconi C, Tedesco-Silva H, et al. Calcineurin inhibitor minimization in the symphony study: observational results 3 years after transplantation. Am J Transplant. 2009;9:1876-1885.
46. Tsai MK, Wu FL, Lai IR, et al. Decreased acute rejection and improved renal allograft survival using sirolimus and low-dose calcineurin inhibitors without induction therapy. Int J Artif Organs. 2009;32:371-380.
47. Tsukasaki K, Hermine O, Bazarbachi A, et al. Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemialymphoma: a proposal from an international consensus meeting. J Clin Oncol. 2009;27:453-459.
48. Gout O, Baulac M, Gessain A, et al. Rapid development of myelopathy after HTLV-I infection acquired by transfusion during cardiac transplantation. N Engl J Med. 1990;322:383-388.
49. Zarranz Imirizaldu JJ, Gomez Esteban JC, Rouco Axpe I, et al. Post-transplantation HTLV-1 myelopathy in three recipients from a single donor. J Neurol Neurosurg Psychiatry. 2003;74:1080-1084. (Pubitemid 36936384)
50. Miyamura F, Kako S, Yamagami H, et al. Successful treatment of young-onset adult T cell leukemia/lymphoma and preceding chronic refractory eczema and corneal injury by allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2009;90(3):397-401.